• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

New hepatitis C virus (HCV) treatment effective

bys25qthea
April 25, 2013
in Chronic Disease, Gastroenterology, Infectious Disease
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. The addition of sofosbuvir to peginterferon-ribavirin was effective at achieving sustained virologic response against HCV genotypes 1, 4, 5 and 6. For HCV genotypes 2 and 3, sofosbuvir and ribavirin was non-inferior to current treatment (peginterferon-ribavirin). 

2. Patients treated with sofosbuvir experienced fewer adverse events overall. 

Evidence Rating Level: 1 (Excellent) 

Study Rundown: There are currently six hepatitis C virus (HCV) genotypes. Since the various genotypes respond differently to treatment, the genotype is one factor that influences the therapy chosen for a chronic HCV carrier. Sofosbuvir is a new HCV polymerase inhibitor that demonstrated high sustained virologic response (SVR) during phase 2 trials. In this study, sofosbuvir was successful at achieving SVR against HCV genotypes 1, 4, 5 and 6 when added to current therapies and was also non-inferior to peginterferon-ribavirin against HCV genotypes 2 and 3. Overall, groups treated with sofosbuvir experienced fewer adverse events. Rapid resistance to treatment has been an issue with past HCV treatments, and sofosbuvir continues to show promise since no viral resistance was detected with deep sequencing assays.

The major limitation to this study was the short follow up time of 12 weeks. Although there was early response to the addition of sofosbuvir, HCV is a chronic infection with various factors influencing relapse. Therefore, relapse rates beyond 12 weeks after sofosbuvir and adverse events from long-term treatment with sofosbuvir will need to be included for future studies.

Click to read the study in NEJM

RELATED REPORTS

Reinfection with hepatitis C virus is highest immediately after treatment in patients on opioid agonist therapy

The VALENCE trial: Sofosbuvir–ribavirin for hepatitis C [Classics Series]

Uptake of hepatitis C treatment in people who inject drugs associated with decreased liver disease

In-Depth [randomized, open-label, active-control]: This two-part phase 3 trial added sofosbuvir to the current standard of care (peginterferon-ribavirin) for HCV genotypes 1, 4, 5 and 6 (NEUTRINO; n=327) and compared sofosbuvir-ribavirin to peginterferon-ribavirin for HCV genotypes 2 and 3 (FISSION; n=499). The primary endpoint was sustained virologic response at 12 weeks after the end of treatment. This was 90% for patients in the NEUTRINO study and 67% in both groups in FISSION. All common adverse events occurred at a lower rate for the sofosbuvir treated group in FISSION. With the exception of anemia, no hematologic adverse events (such as decreased lymphocyte count, neutrophil count, platelet count) were observed in the sofosbuvir-ribavirin group.

By Jonathan Liu and Mitalee Patil

More from this author: PFO Closure equivalent to medical management in prevention of recurrent stroke, Combo antifungal therapy most effective treatment for cryptococcal meningitis,  Rhinovirus, genes may interact to increase risk of childhood asthma, Functional MRI map for physical pain identified, Glutamine and antioxidant supplementation provide no benefit for critically-ill patients

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. Content is produced in accordance with fair use copyrights solely and strictly for the purpose of teaching, news and criticism. No benefit, monetary or otherwise, is realized by any participants or the owner of this domain. 

Tags: HCVhepatitis CHepCpeginterferonribavirinsofosbuvir
Previous Post

Gut microbes implicated in stroke and heart attacks: new dietary link

Next Post

Health education module reduces parasitic infections

RelatedReports

Patients with low back pain or pain at multiple sites at highest risk for chronic opioid use
Chronic Disease

Reinfection with hepatitis C virus is highest immediately after treatment in patients on opioid agonist therapy

August 25, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Infectious Disease Classics

The VALENCE trial: Sofosbuvir–ribavirin for hepatitis C [Classics Series]

August 17, 2022
Screening insufficient for newborns exposed to hepatitis C virus
Chronic Disease

Uptake of hepatitis C treatment in people who inject drugs associated with decreased liver disease

July 26, 2022
#VisualAbstract: Ruxolitinib shows long-term safety and efficacy in inadequately controlled polycythaemia vera without splenomegaly
StudyGraphics

#VisualAbstract: Ruxolitinib shows long-term safety and efficacy in inadequately controlled polycythaemia vera without splenomegaly

May 26, 2022
Next Post
Health education module reduces parasitic infections

Health education module reduces parasitic infections

Liver transplant prolongs life in metastatic colorectal cancer

Liver transplant prolongs life in metastatic colorectal cancer

Drainage for hemopericardium is safe and reduces hospital stay

Drainage for hemopericardium is safe and reduces hospital stay

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Expectant management of patent ductus arteriosus noninferior to early ibuprofen use
  • Exhaled volatile organic compounds predict bronchopulmonary dysplasia in preterm infants
  • Wellness Check: Mental Health
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options